Protocol for a pharmacogenomic study on individualised antipsychotic drug treatment for patients with schizophrenia

Author:

Su YiORCID,Yu HaoORCID,Wang Zhiren,Liu Sha,Zhao Liansheng,Fu Yingmei,Yang Yongfeng,Du Bo,Zhang Fuquan,Zhang Xiangrong,Huang Manli,Hou Cailan,Huang Guoping,Su Zhonghua,Peng Mao,Yan Ran,Zhang Yuyanan,Yan HaoORCID,Wang Lifang,Lu Tianlan,Jia Fujun,Li Keqing,Lv Luxian,Wang Hongxing,Yu Shunying,Wang QiangORCID,Tan YunlongORCID,Xu YongORCID,Zhang Dai,Yue Weihua

Abstract

Background Schizophrenia is a severe and complex psychiatric disorder that needs treatment based on extensive experience. Antipsychotic drugs have already become the cornerstone of the treatment for schizophrenia; however, the therapeutic effect is of significant variability among patients, and only around a third of patients with schizophrenia show good efficacy. Meanwhile, drug-induced metabolic syndrome and other side-effects significantly affect treatment adherence and prognosis. Therefore, strategies for drug selection are desperately needed. In this study, we will perform pharmacogenomics research and set up an individualised preferred treatment prediction model. Aims We aim to create a standard clinical cohort, with multidimensional index assessment of antipsychotic treatment for patients with schizophrenia. Method This trial is designed as a randomised clinical trial comparing treatment with different kinds of antipsychotics. A total sample of 2000 patients with schizophrenia will be recruited from in-patient units from five clinical research centres. Using a computer-generated program, the participants will be randomly assigned to four treatment groups: aripiprazole, olanzapine, quetiapine and risperidone. The primary outcomes will be measured as changes in the Positive and Negative Syndrome Scale of schizophrenia, which reflects the efficacy. Secondary outcomes include the measure of side-effects, such as metabolic syndromes. The efficacy evaluation and side-effects assessment will be performed at baseline, 2 weeks, 6 weeks and 3 months. Results This trial will assess the efficacy and side effects of antipsychotics and create a standard clinical cohort with a multi-dimensional index assessment of antipsychotic treatment for schizophrenia patients. Conclusion This study aims to set up an individualized preferred treatment prediction model through the genetic analysis of patients using different kinds of antipsychotics.

Publisher

Royal College of Psychiatrists

Subject

Psychiatry and Mental health

Reference34 articles.

1. Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors

2. A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS

3. Principal components analysis corrects for stratification in genome-wide association studies

4. 26 Guy, W . ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.

5. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment

全球学者库

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-88110370

www.globalauthorid.com

TOP

Copyright © 2019-2022 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3